Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
08/26/2015
Trade Name:
Edurant
Generic Name or Proper Name (*):
rilpivirine
Indications Studied:
HIV-1 infection in treatment-naïve pediatric patients from 12 to less than 18
Label Changes Summary:
*Expanded the indication from adults to pediatric patients 12 to less than 18 years and weighing at least 32 kg. *Safety, efficacy and PK were evaluated in an open-label, Phase 2 trial that enrolled 36 antiretroviral treatment-naïve, HIV-1 infected pediatric patients. *Safety and effectiveness in pediatric patients less than 12 years have not been established. *Information added to Warnings on pediatric depression: During the Phase 2 trial, the incidence of depressive disorders was 19.4% (7/36). Most events were mild or moderate. The incidence of Grade 3 and 4 depressive disorders was 5.6% (2/36). Suicidal ideation and suicide attempt were reported in 1 subject. *The most common ADRs reported in at least 2 subjects (regardless of severity) include headache (19.4%), depression (19.4%), somnolence (13.9%), nausea (11.1%), dizziness (8.3%), abdominal pain (8.3), vomiting (5.6%) and rash (5.6%). *Information on dosing, adverse reactions, abnormal adrenal function, PK, and clinical trial
Product Labeling:
Labeling
BPCA(B) and PREA(P):
B, P
Sponsor:
Janssen
NNPS:
FALSE
-
-